Genotypic and Phenotypic Correlates of Resistance to Aspirin (ARSENAL)

George Washington University (GW)

Status: Completed

Conditions: Platelet Dysfunction Due to Aspirin

Treatments: Drug: aspirin

Study type: Interventional

Funder types: Other

Identifiers

NCT01361620

AR2011

Details and patient eligibility

About

The study seeks to identify genomic markers associated with aspirin resistance.

Full description

Not desired

Enrollment: 190 patients

Sex: All

Ages: 40 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Volunteers 40 to 80 years old willing to sign consent and take 81 mg of aspirin for 7 - 10 days and return for laboratory testing.

Exclusion criteria

• Patient requiring more than 81 mg aspirin daily

• Known GI bleeding attributed to ASA

• Active peptic ulcer disease or history within the last year

• Known aspirin allergy

• Current use of:

  • warfarin,
  • heparin,
  • NSAIDs (except aspirin),
  • clopidogrel,
  • dipyridamole,
  • fish-oil/omega 3 supplements,

• Women of childbearing potential who are pregnant, planning to become pregnant or nursing.

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

190 participants in 1 patient group

Aspirin

Other group

Description:

All subjects took 7-10 days of 81 mg aspirin

Treatment:

Drug: aspirin